| 引用本文: | 赵一,张露平,白玉琦,杨保军,冯力民.生殖健康专题+左炔诺孕酮宫内缓释系统与地屈孕酮在围绝经期女性子宫内膜增生不伴非典型增生患者中的临床疗效观察[J].中国临床新医学,,():-. |
| zhaoyi.生殖健康专题+左炔诺孕酮宫内缓释系统与地屈孕酮在围绝经期女性子宫内膜增生不伴非典型增生患者中的临床疗效观察[J].中国临床新医学,,():-. |
|
| 摘要: |
| 目的 探讨左炔诺孕酮宫内缓释系统(LNG-IUS)与地屈孕酮治疗围绝经期子宫内膜增生不伴非典型增生(EH)患者的临床疗效及安全性。方法 选取2022年6月至2025年6月北京天坛医院收治的经病理诊断为子宫内膜增生不伴非典型增生的患者71例为研究对象,分为LNG-IUS组(LNG-IUS治疗,n=37)和地屈孕酮组(地屈孕酮治疗,n=34),比较两组临床疗效,月经情况、子宫内膜情况,以及不良反应。结果 LNG-IUS组及地屈孕酮组治疗前后,月经经期及子宫内膜厚度比较差异均有统计学意义(P<0.05)；治疗前两组月经经期、子宫内膜厚度比较差异无统计学意义(P>0.05),治疗后两组月经经期、子宫内膜厚度均降低,且LNG-IUS组低于地屈孕酮组(P<0.001)；LNG-IUS组治疗有效率高于地屈孕酮组,但两组有效率比较差异无统计学意义(P>0.05)；LNG-IUS组的不良反应率低于地屈孕酮组,但两组比较差异无统计学意义(P>0.05)。结论 LNG-IUS与地屈孕酮均可有效改善子宫内膜增生不伴非典型增生患者的月经异常及子宫内膜厚度,其中LNG-IUS治疗有效率更高、不良反应发生率更低,临床应用疗效及安全性更具优势。 |
| 关键词: 左炔诺孕酮宫内缓释系统 地屈孕酮 子宫内膜增生 围绝经期 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Clinical Efficacy of Levonorgestrel-Releasing Intrauterine System versus Dydrogesterone in Perimenopausal Women with Endometrial Hyperplasia Without Atypia |
|
zhaoyi
|
|
Beijing Tiantan Hospital, Capital Medical University
|
| Abstract: |
| Objective To evaluate the clinical efficacy and safety of levonorgestrel-releasing intrauterine system (LNG-IUS) versus dydrogesterone for the treatment of perimenopausal patients with endometrial hyperplasia without atypia.Methods A total of 71 patients pathologically diagnosed with endometrial hyperplasia without atypia were recruited from Beijing Tiantan Hospital between June 2022 and June 2025. All participants were allocated to the LNG-IUS group (n=37) receiving LNG-IUS insertion and the dydrogesterone group (n=34) treated with oral dydrogesterone. Clinical efficacy, menstrual characteristics, endometrial thickness and adverse reaction profiles were compared between the two groups.Results Significant improvements in menstrual duration and endometrial thickness were observed after treatment in both groups (P<0.05). Baseline menstrual duration and endometrial thickness were comparable between the two groups (P>0.05). After intervention, both parameters were markedly reduced in the two groups, with significantly lower values in the LNG-IUS group relative to the dydrogesterone group (P<0.001). Although the LNG-IUS group exhibited a higher overall response rate and a lower incidence of adverse reactions than the dydrogesterone group, the differences did not reach statistical significance (P>0.05).Conclusion Both LNG-IUS and dydrogesterone can effectively alleviate menstrual abnormalities and reduce endometrial thickness in patients with endometrial hyperplasia without atypia. LNG-IUS yields better clinical efficacy and safety profiles with a higher therapeutic response rate and fewer adverse events, making it a preferable option in clinical practice. |
| Key words: Levonorgestrel-releasing intrauterine system Dydrogesterone Endometrial hyperplasia Perimenopause |
